Zogenix to Host Investor Meeting on October 13, 2011
SAN DIEGO, Oct 12, 2011 (GlobeNewswire via COMTEX) --
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain, announced today that it will host an investor meeting on Thursday, October 13, 2011, from 7:30 am - 11:30 am ET in New York.
The meeting will be hosted by Zogenix's senior management team, including:
-- Roger Hawley, Chief Executive Officer -- Stephen Farr, President and Chief Operating Officer -- Ann Rhoads, Chief Financial Officer -- Cynthia Robinson, Chief Development Officer
Physician guest speakers at the investor meeting include:
-- Richard L. Rauck, M.D., Executive Director, Center for Clinical Research in Pain; Pain Fellowship Director, Wake Forest University Health Sciences; President, Carolinas Pain Institute -- Ira M. Turner, M.D., Island Neurological Associates, Plainview, NY
The agenda for the meeting is listed below:
7:30 -- 8:00 am Registration
8:00 -- 8:15 am Introduction and Company Overview
8:15 -- 9:15 am Zohydro Phase 3 (study 801) Top Line Efficacy Results and Opioid Landscape, with presentations by Dr. Cynthia Robinson, Dr. Stephen Farr, and Dr. Richard Rauck
9:15 -- 9:45 am Zohydro and Physician Panel Q&A Session
9:45 -- 10:00 am Break
10:00 -- 10:30 am SUMAVEL DosePro Update and Physician Presentation, with presentations by Dr. Stephen Farr and Dr. Ira Turner
10:30 -- 10:45 am Relday Overview
10:45 -- 11:00 am DosePro Development Overview
11:00 -- 11:30 am SUMAVEL DosePro, Relday and DosePro Q&A Session
The investor meeting will be webcast live and archived for 30 days on the investor relations section of the Zogenix website at www.zogenix.com.
Zogenix, Inc. (Nasdaq:ZGNX), with offices in San Diego and Emeryville, California, is a pharmaceutical company commercializing and developing products for the treatment of central nervous system disorders and pain. Zogenix's first commercial product, SUMAVEL(R) DosePro(R) (sumatriptan injection) Needle-free Delivery System, was launched in January 2010 for the acute treatment of migraine and cluster headache. Zogenix's lead product candidate, Zohydro(TM) (hydrocodone bitartrate), is a novel, oral, single-entity (without acetaminophen) extended-release capsule formulation currently in Phase 3 clinical trials for the management of moderate to severe chronic pain in patients requiring around-the-clock opioid therapy. Zogenix's second DosePro product candidate, Relday(TM), is a proprietary, long-acting injectable formulation of risperidone for the treatment of schizophrenia.
This news release was distributed by GlobeNewswire, www.globenewswire.com
CONTACT: INVESTORS: Zack Kubow | The Ruth Group 646.536.7020 | firstname.lastname@example.org MEDIA: Victoria Aguiar | The Ruth Group 646.536.7013 | email@example.com